EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer

Martin Johnson iD, Carlos Serra Traynor iD, Karthick Vishwanathan iD, Philip Overend iD, Ryan Hartmaier iD, Aleksandra Markovets iD, Juliann Chmielecki iD, Ganesh M Mugundu iD, J Carl Barrett iD, Helen Tomkinson iD, Suresh S Ramalingam iD

Clinical Pharmacology & Therapeutics · 2024-02 · 115 (2) · 349-360

DOI: 10.1002/cpt.3113 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 21.12.2023. Verfasst von Martin Johnson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This exploratory, post hoc analysis aimed to model circulating tumor DNA (ctDNA) dynamics and predict disease progression in patients with treatment‐naïve locally advanced/metastatic epidermal growth factor receptor mutation (EGFRm)‐positive non‐small cell lung cancer, from the FLAURA trial (NCT02296125). Patients were randomized 1:1 and received osimertinib 80 mg once daily (q.d.) or comparator EGFR‐TKIs (gefitinib 250 mg q.d. or erlotinib 150 mg q.d.). Plasma was collected at baseline and multiple timepoints until treatment discontinuation. Patients with Response Evaluation Criteria in Solid Tumors (RECIST) imaging data and detectable EGFR mutations (Ex19del/L858R) at baseline and ≥ 3 additional timepoints were evaluable. Joint modeling was conducted to characterize the relationship between longitudinal changes in ctDNA and probability of progression‐free survival (PFS). A Bayesian joint model of ctDNA and PFS was developed solving differential equations with the ctDNA dynamics and the PFS time‐to‐event probability. Of 556 patients, 353 had detectable ctDNA at baseline. Evaluable patients (with available imaging and ≥ 3 additional timepoints, n = 320; ctDNA set) were divided into training ( n = 259) and validation ( n = 61) sets. In the validation set, the model predicted a median PFS of 17.7 months (95% confidence interval (CI): 11.9–28.3) for osimertinib ( n = 23) and 9.1 months (95% CI: 6.3–14.8) for comparator ( n = 38), consistent with observed RECIST PFS (16.4 months and 9.7, respectively). The model demonstrates that EGFRm ctDNA dynamics can predict the risk of disease progression in this patient population and could be used to predict RECIST‐defined disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCirculating Tumor DNAIndolesLung NeoplasmsPyrimidinesHumansBayes TheoremDisease ProgressionErbB ReceptorsMutationProtein Kinase Inhibitors

Substanzen

AcrylamidesAniline CompoundsAntineoplastic AgentsCirculating Tumor DNAErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Boston, Massachusetts, USA.
  • Oncology Biometrics, Oncology, R&D, AstraZeneca, Cambridge, UK.
  • Translational Medicine, Oncology, R&D, AstraZeneca, Boston, Massachusetts, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA.

ORCID-Profile: Martin Johnson, Carlos Serra Traynor, Karthick Vishwanathan, Philip Overend, Ryan Hartmaier, Aleksandra Markovets, Juliann Chmielecki, Ganesh M Mugundu, J Carl Barrett, Helen Tomkinson, Suresh S Ramalingam

Zitieren

APA

Johnson, M., Serra Traynor, C., Vishwanathan, K., Overend, P., Hartmaier, R., Markovets, A., Chmielecki, J., Mugundu, G. M., Barrett, J. C., Tomkinson, H., & Ramalingam, S. S. (2024). Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics, 115(2), 349-360. https://doi.org/10.1002/cpt.3113

Vancouver

Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A, et al. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 2024;115(2):349-360. doi:10.1002/cpt.3113

BibTeX
@article{Johnson2024,
  author = {Johnson, Martin and Serra Traynor, Carlos and Vishwanathan, Karthick and Overend, Philip and Hartmaier, Ryan and Markovets, Aleksandra and Chmielecki, Juliann and Mugundu, Ganesh M and Barrett, J Carl and Tomkinson, Helen and Ramalingam, Suresh S},
  title = {Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {115},
  number = {2},
  pages = {349--360},
  doi = {10.1002/cpt.3113}
}
Kostenlos starten →